Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PAH
Pharma
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
The FDA has signed off on Opsynvi, a tablet which combines J&J’s Opsumit and United's Adcirca, as a treatment for pulmonary arterial hypertension.
Kevin Dunleavy
Mar 25, 2024 11:05am
FDA faces lawsuit from United on its Liquidia review process
Feb 21, 2024 2:31pm
Janssen rounds out final live talk of 2022 for PH nurses
Dec 7, 2022 10:31am
EMA examines key Actelion med Uptravi following 5 patient deaths in France
Feb 14, 2017 10:50am
Can Adempas meet Bayer's growth expectations after a canceled trial?
May 17, 2016 7:36am
